e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Medical treatment of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Acetazolamide, chronic mountain sickness and pulmonary hypertension
J. P. Richalet, M. Maignan, M. Rivera-Ch, I. Pham, F. Leon-Velarde (Bobigny, France; Lima, Peru)
Source:
Annual Congress 2008 - Medical treatment of pulmonary hypertension
Session:
Medical treatment of pulmonary hypertension
Session type:
Oral Presentation
Number:
3182
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. P. Richalet, M. Maignan, M. Rivera-Ch, I. Pham, F. Leon-Velarde (Bobigny, France; Lima, Peru). Acetazolamide, chronic mountain sickness and pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 3182
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Late Breaking Abstract - Developing the pneumonia-optimized ratio for community-acquired pneumonia: an easy, inexpensive and accurate prognostic biomarker
Should we screen for hereditary pulmonary hypertension?
Related content which might interest you:
High-altitude pulmonary hypertension: a pathophysiological entity to different diseases
Source: Eur Respir J 2003 Dec 01;22(6):1019-1025
Year: 2003
Travel to high altitude with pre-existing lung disease
Source: Eur Respir J 2007; 29: 770-792
Year: 2007
Hypoxaemia in chronic obstructive pulmonary disease patients during a commercial flight
Source: Eur Respir J 2005; 25: 725-730
Year: 2005
Exercise pathophysiology in patients with chronic mountain sickness
Source: Annual Congress 2011 - Physiological basis of respiratory disease
Year: 2011
Fitness for flying and diving
Source: Annual Congress 2006 - PG3 - Update on occupational and environmental lung disease, including "bring your own cases" for interactive discussion
Year: 2006
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history
Source: Eur Respir Rev 2009; 18: 170-173
Year: 2009
High-altitude disease
Source: Respipedia Article
Year: 2017
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
Calcium channel activity in lowlanders and in highlanders with pulmonary hypertension due to chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 99s
Year: 2002
Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics
Source: Eur Respir J 2012; 40: 1401-1409
Year: 2012
Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
The effects of national lockdown on incidence of acute exacerbation of chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021
The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2007; 30: 922-927
Year: 2007
Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
The rate of pulmonary thromboembolism in acute exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 297s
Year: 2005
Pulmonary hypertension in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 892-905
Year: 2003
ERS statement on chronic thromboembolic pulmonary hypertension
Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept